Shield Therapeutics PLC Composition of Matter Patent Granted on Feraccru® (1655J)
September 07 2016 - 2:37AM
UK Regulatory
TIDMSTX TIDMSTXW
RNS Number : 1655J
Shield Therapeutics PLC
07 September 2016
Shield Therapeutics plc
("Shield" or the "Company")
Composition of Matter Patent Granted on Feraccru(R)
New patent adds significant protection to Feraccru(R) and
extends exclusivity until at least 2034
London, UK, 07 September 2016. Shield Therapeutics plc
(LSE:STX), a specialty pharmaceutical company focused on secondary
care, is pleased to announce that the UK Intellectual Property
Office (UKIPO) has granted a composition of matter patent
protecting the Company's lead product Feraccru(R), which received
marketing authorisation across Europe in February 2016 for the
treatment of adults with Iron Deficiency Anaemia in patients with
inflammatory bowel disease. Feraccru(R) is currently in the early
stages of commercialisation in Europe, having been launched in the
UK in June 2016.
UK Patent GB2531742 is entitled "Polymorphs of Ferric Maltol"
and significantly expands Feraccru's intellectual property
portfolio by protecting the active substance of Feraccru(R) through
to at least 2034. Prior to this grant, Feraccru(R) intellectual
property rights were based on manufacturing and use patents
initially through to 2023 before the application of any patent
extensions granted following marketing authorisations, for example
a Supplementary Protection Certificate in the European Economic
Area.
Carl Sterritt, Founder and Chief Executive Officer, commented:
"I am delighted that such a highly regarded body as the UKIPO has
granted Shield a composition of matter claim to the active
substance in Feraccru(R). In doing so, this has significantly added
to the breadth of the IP for Feraccru(R) as well as providing a
lengthy extension to that protection. Allowance at the UKIPO is an
indicator of the protection that we are anticipating in other
territories when the national phase is entered in April 2017.
Shield intends to seek protection across a broad range of
geographies at that time, and such composition of matter protection
should enable Shield to prevent third parties from manufacturing or
selling the product for any use until at least 2034."
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)191 511 8507
Carl Sterritt, Chief Executive
Officer
Richard Jones, Chief Financial
Officer
NOMAD
Liberum Capital Limited
Christopher Britton
Steve Pearce +44 (0)20 3100 2222
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott
Matthew Neal
Lindsey Neville
Hendrik Thys
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals which address areas of unmet
medical need. The Company has a marketed product, Feraccru(R), for
the treatment of iron deficiency anaemia (IDA). In addition, the
Company is developing PT20, a late-stage pharmaceutical for the
treatment of systemic phosphate accumulation (hyperphosphatemia).
Shield Therapeutics, headquartered in London, is listed on LSE's
AIM under the ticker STX. For more information please visit
www.shieldtherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGUBPBUPQUQM
(END) Dow Jones Newswires
September 07, 2016 02:37 ET (06:37 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024